Scarica l'app Stockscreener
1.0442
11.44%
-0.1358
Precedente Chiudi:
$1.18
Aprire:
$1.15
Volume 24 ore:
623.63K
Relative Volume:
0.21
Capitalizzazione di mercato:
$8.92M
Reddito:
$34.07M
Utile/perdita netta:
$-20.13M
Rapporto P/E:
-0.0808
EPS:
-12.92
Flusso di cassa netto:
$-24.90M
1 W Prestazione:
-6.70%
1M Prestazione:
-12.18%
6M Prestazione:
+6.65%
1 anno Prestazione:
-55.53%
Intervallo 1D:
$1.03
$1.16
Intervallo di 1 settimana:
$0.96
$1.87
Portata 52W:
$0.61
$2.46
Biofrontera Inc Stock (BFRI) Company Profile
Nome
Biofrontera Inc
Settore
Telefono
781-245-1325
Indirizzo
120 PRESIDENTIAL WAY,, WOBURN
Confronta BFRI con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BFRI
Biofrontera Inc
|
1.0442 | 8.92M | 34.07M | -20.13M | -24.90M | -12.92 |
|
ZTS
Zoetis Inc
|
164.52 | 73.93B | 9.15B | 2.43B | 2.31B | 5.32 |
|
HLN
Haleon Plc Adr
|
9.15 | 41.66B | 14.26B | 1.55B | 0 | 0.3383 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.09 | 41.52B | 30.27B | 1.93B | 3.45B | 0.6044 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
21.04 | 23.79B | 16.77B | -959.00M | 1.37B | -0.85 |
|
VTRS
Viatris Inc
|
11.62 | 13.88B | 15.05B | -883.30M | 1.89B | -0.74 |
Biofrontera Inc Borsa (BFRI) Ultime notizie
Biofrontera says last patient completed one-year follow-up in Ameluz-PDT study - TipRanks
Biofrontera Inc. Announces Achievement of Key Milestone In - GlobeNewswire
Biofrontera Inc. Announces Achievement of Key Milestone In Phase 3 Study Of Ameluz®-Photodynamic Therapy (PDT) In The Treatment Of Superficial Basal Cell Carcinoma (sBCC) - Yahoo Finance
Biofrontera Inc. Announces 100 RhodoLED® XL Machines Now Placed in US Market - The Manila Times
Biofrontera Hits Major Milestone: 100th RhodoLED® XL Lamp Installed as PDT Treatment Demand Surges - StockTitan
Opendoor Technologies Inc (OPEN-Q) QuotePress Release - The Globe and Mail
Financial Contrast: Biofrontera (NASDAQ:BFRI) versus Amicus Therapeutics (NASDAQ:FOLD) - Defense World
Why Stitch Fix Shares Are Trading Higher By Around 21%; Here Are 20 Stocks Moving Premarket - Benzinga
Biofrontera Inc (BFRI:UR): Stock Price, Quote and News - BNN Bloomberg
Biofrontera to Present at Benchmark's Discovery Investor Conference in NYC - StockTitan
Biofrontera Inc. announced that it expects to receive $4.2 million in funding - Marketscreener.com
Biofrontera Closes a $4.2 Million Senior Secured Convertible Note - citybiz
Biofrontera Inc. Closes a $4.2 Million Senior Secured Convertible Note - GlobeNewswire
Biofrontera Secures $4.2M for Strategic Growth Initiatives - TipRanks
Biofrontera Secures $4.2M Financing Through Convertible Note Deal with Key Shareholders | BFRI Stock News - StockTitan
Biofrontera AG announced that it has received $4.2 million in funding - Marketscreener.com
Biofrontera Third Quarter 2024 Earnings: Misses Expectations - Simply Wall St
Earnings call: Biofrontera reports modest revenue growth in Q3 2024 - Investing.com
Biofrontera Inc. (NASDAQ:BFRI) Q3 2024 Earnings Call Transcript - Insider Monkey
Biofrontera Inc. (BFRI) Quarterly 10-Q Report - Quartzy
ARMISTICE CAPITAL, LLC Acquires New Stake in Biofrontera Inc - GuruFocus.com
Biofrontera Inc. Reports Q3 2024 Earnings Growth - TipRanks
Biofrontera Inc. (BFRI) Reports Q3 Loss, Lags Revenue Estimates - MSN
Biofrontera Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Biofrontera Inc. Reports Third Quarter and Nine-Month 2024 Financial Results and Provides Business Update - GlobeNewswire
Biofrontera Reports Record Ameluz Volume, Phase 3 Study Shows 76% Clearance Rate | BFRI Stock News - StockTitan
Siga Technologies (SIGA) Sees Significant Stock Decline Amidst P - GuruFocus.com
Rosalind Advisors, Inc. Reduces Stake in Biofrontera Inc. - GuruFocus.com
Biofrontera Inc. to Report Third Quarter Financial Results on November 13, 2024 - Yahoo Finance
Biofrontera reports breakthrough in skin cancer treatment By Investing.com - Investing.com Australia
Biofrontera stock climbs as drug-device succeeds in Phase III skin cancer trial - Yahoo Finance
Biofrontera Announces Promising Phase 3 Study Results - TipRanks
Biofrontera reports breakthrough in skin cancer treatment - Investing.com
Biofrontera announces results in Phase 3 study of Ameluz-PDT for sBCC - TipRanks
Biofrontera Inc. Announces Highly Significant Results In Phase 3 Study Of Ameluz®-Photodynamic Therapy (PDT) Regarding The Treatment Of Superficial Basal Cell Carcinoma (sBCC) - GlobeNewswire
Actinic Keratosis Treatment Market Expected to Reach Huge - openPR
Rosalind Advisors, Inc. Reduces Stake in Biofrontera Inc - Yahoo Finance
Biofrontera locks phase 3 sBCC study database for analysis By Investing.com - Investing.com Australia
Biofrontera locks phase 3 sBCC study database for analysis - Investing.com India
Biofrontera Inc. Announces Database Lock Of Phase 3 Study - GlobeNewswire
Biofrontera Inc. Announces Database Lock Of Phase 3 Study Of Ameluz®-Photodynamic Therapy (PDT) In The Treatment Of Superficial Basal Cell Carcinoma (sBCC) - StockTitan
BFRI’s Stock Market Odyssey: A Year of Growth, Decline, and Resilience - The InvestChronicle
Mass. Biotech Receives FDA Approval - Streetwise Reports
Roth/MKM sets Biofrontera target at $16, reiterates buy rating By Investing.com - Investing.com South Africa
Roth/MKM sets Biofrontera target at $16, reiterates buy rating - Investing.com India
What was Biofrontera Inc (BFRI)’s performance in the last session? - US Post News
Biofrontera says FDA approves use of up to 3 tubes of Ameluz topical gel 10% - TipRanks
Biofrontera’s Ameluz Gel FDA Approval for Higher Dosage - TipRanks
FDA approves expanded use of Biofrontera's Ameluz for AK - Investing.com
FDA Approves Use of Up To Three Tubes of Biofrontera Inc.'s Ameluz (aminolevulinic acid HCI) Topical Gel, 10% In One Treatment - The Manila Times
Biofrontera Inc Azioni (BFRI) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.97%
0.62%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):